Last updated: 2026-09-16 12:10:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Crescent Biopharma, Inc. (CBIO) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $18,80, with a market capitalisation of $731,05M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $8,72 to $27,41. This page covers its latest market performance, valuation, price trends and company information.
$731,05M | |
$19,60 | |
$555,00 | |
$2,83 | |
$19,68 | |
313,28K | |
344,65K | |
-- | |
$27,41 | |
$8,72 | |
-- | |
-- |
Crescent Biopharma, Inc. (CBIO) is trading at $19,68 in pre-market trading as of 2026-09-15 23:31:00, up 0,01% ($0,00) from the previous close of $19,68
Pre-market trading shows how investors are pricing CBIO before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Over the past seven days, Crescent Biopharma, Inc. (CBIO) moved from $20,88 to $18,80, representing a decline of 9,94% ($2,08).
The stock traded between $18,40 and $21,53 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 327,09 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 54,0%
CBIO is currently trading at $18,80, placing it 54,0% of the way from its 52-week low of $8,72 to its 52-week high of $27,41. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 44 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Crescent Biopharma, Inc. (CBIO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.